株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Brexpiprazole(統合失調症治療薬):市場の予測と分析

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 299184
出版日 ページ情報 英文 58 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
Brexpiprazole(統合失調症治療薬):市場の予測と分析 Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022
出版日: 2014年02月28日 ページ情報: 英文 58 Pages
概要

Brexpiprazoleは、D3/D2受容体の部分的作動薬(パーシャルアゴニスト:ただしD2により強く作用)で、大塚製薬で現在開発中です。部分的作動薬としてはcariprazine(D3の部分的作動薬)と同様に、高血圧/低血圧時のドーパミン作動トーンを安定化させる働きをします。Brexpiprazoleは複数のモノアミン系(5-HT1Aの部分的作動薬や5-HT2A a1受容体の拮抗薬など)に対して作用し、それが錐体外路症状(EPS)の発生を抑えるものと考えられていますが、一方でD2受容体としても機能しています。Brexpiprazoleはまた5-HT7受容体の拮抗薬であり、抗うつ剤として有効です。他にも様々な作用プロファイルがあり、認知症・ADHD・PTSD・睡眠障害・大うつ病性障害(MDD)などへの適用が研究されています。その名が示すとおり、Brexpiprazoleは2015年4月に特許が失効するAbilify(大塚製薬:アリピプラゾール)の後継薬となる製品としてみなされています。

当レポートでは、統合失調症の治療薬の一つ、Brexpiprazoleの世界市場について分析し、統合失調症の概要や治療法、Brexpiprazoleの商品情報(特色・効能・安全性など)と競争力、競合する企業・薬品の概要、市場機会とアンメットニーズ、治験の進行状況、世界の主要国における市場販売額の見通し(今後10年間分)などを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因と病態
    • 病因
    • 病態
  • 症状

第4章 疾患の管理

  • 診断
    • 主観的評価
    • 疾患の分類
  • 治療法の概要
    • 統合失調症に関連する急性興奮の治療
    • 統合失調症の維持療法

第5章 競合企業の評価

  • 概要
  • 競合企業の戦略的評価

第6章 市場機会とアンメットニーズ

  • アンメットニーズの概要
    • 一般的な認知度
    • 早期診断・治療
    • 長期間作用型・最先端のドラッグデリバリーシステム
    • 陰性症状・認知症状の効果的な管理
  • ギャップ分析
    • 長期間作用型のドラッグデリバリー
    • 陰性症状・認知症状の治療

第7章 パイプライン評価

  • 概要
  • 初期段階にあるパイプライン製品の評価
  • 新たな治療アプローチ
    • 陰性症状
    • 認知症状
  • 長期間作用型のドラッグデリバリー
  • 技術動向の分析
  • 治験段階にある主な医薬品

第8章 Brexpiprazoleについて

  • 概要
  • 効能
  • 安全性
    • 投与・剤形方法
    • 臨床面での潜在的な位置づけ
    • 商業面での潜在的な位置づけ
    • 価格設定と医療費償還
  • SWOT分析
  • 予測

第9章 付録

図表一覧

目次
Product Code: GDHC367DFR

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Brexpiprazole is a D2-preferring D3/D2 receptor partial agonist in development by Otsuka. As a partial agonist, like cariprazine (a D3 partial agonist), brexpiprazole helps to stabilize dopaminergic tone in periods of hyper- or hypoactivity. Brexpiprazole has broad activity across multiple monoamine systems, including 5-HT1A partial agonism and antagonism at 5-HT2A a1 receptors, which may lessen the occurrence of EPS, although it acts on D2 receptors (Stahl, 2013). Brexpiprazole is also an antagonist at 5-HT7 receptors, which may make it useful as an antidepressant. Given its diverse activity profile, it is also being investigated in dementia, ADHD, PTSD, sleep disorders, and MDD. As its name suggests, brexpiprazole may be considered as a successor to Otsuka's Abilify (aripiprazole), which faces patent expiration in April 2015.

Scope

  • Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Brexpiprazole including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Brexpiprazole for the top seven countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Brexpiprazole performance
  • Obtain sales forecast for Brexpiprazole from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis
    • 4.1.1. Subjective Assessments
    • 4.1.2. Disease Subtypes
  • 4.2. Treatment Overview
    • 4.2.1. Treatment of Acute Agitation Associated with Schizophrenia
    • 4.2.2. Maintenance Treatment of Schizophrenia

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Unmet Needs Overview
    • 6.1.1. Public Awareness
    • 6.1.2. Early Diagnosis and Treatment
    • 6.1.3. Long-Acting and Advanced Drug Delivery Systems
    • 6.1.4. Effective Management of Negative and Cognitive Symptom Domains
  • 6.2. Gap Analysis
    • 6.2.1. Long-Acting Drug Delivery
    • 6.2.2. Treatment of Negative and Cognitive Symptoms

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Early-Stage Pipeline Assessment
  • 7.3. Novel Therapeutic Approaches
    • 7.3.1. Negative Symptoms
    • 7.3.2. Cognitive Symptoms
  • 7.4. Long-Acting Drug Delivery
  • 7.5. Technology Trends Analysis
  • 7.6. Key Drugs in Clinical Development

8. Brexpiprazole

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
    • 8.3.1. Dosing and Formulation
    • 8.3.2. Potential Clinical Positioning
    • 8.3.3. Potential Commercial Positioning
    • 8.3.4. Pricing and Reimbursement

8.4. SWOT Analysis

  • 8.5. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosis and Treatment Rates
    • 9.4.2. Adherence Rates
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Generic Erosion
    • 9.4.5. Pricing of Pipeline Agents
  • 9.5. Key Opinion Leaders
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Reviewers
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Symptom Clusters of Schizophrenia
  • Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis
  • Table 3: Development-Based Classification of Antipsychotic Drugs
  • Table 4: Receptor Binding Profiles of Atypical Antipsychotics
  • Table 5: Guidelines for the Treatment of Schizophrenia
  • Table 6: Leading Branded Treatments for Schizophrenia, 2013
  • Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014
  • Table 8: Unmet Needs - Current Level of Attainment
  • Table 9: Clinical Unmet Needs - Gap Analysis, 2013
  • Table 10: Technological Trends Analytic Framework in the Schizophrenia Pipeline, 2014
  • Table 11: Pipeline Candidates in Development for Schizophrenia, 2014
  • Table 12: Comparison of Novel Therapeutic Classes in Development for Schizophrenia, 2013
  • Table 13: Product Profile - Brexpiprazole
  • Table 14: Brexpiprazole SWOT Analysis, 2014
  • Table 15: Global Sales Forecasts ($m) for Brexpiprazole, 2012-2022

List of Figures

  • Figure 1: Schizophrenia - Pipeline Drugs by Target, 2014
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Schizophrenia, 2012-2022
Back to Top